MedArmor Launches AI-Powered Genomic Screening & Preventive Healthcare in Ho Chi Minh City
On June 13th, 2025, a significant advancement in Vietnam’s healthcare unfolded at Ho Chi Minh City, Vietnam. The grand opening of MedArmor’s flagship clinic marked the company’s expansion into Southeast Asia, marking the beginning of a new era in preventive and personalized medicine. As a registered brand under Core8 Group, MedArmor introduces a unique combination of AI-driven technology and international medical expertise to Vietnam. The clinic integrates proprietary 4DMatrix AI-powered genomic screening, innovative diagnostic platforms, and cross-border clinical partnerships to deliver next-generation healthcare services that were previously unavailable in the region.
Core8 CEO Mike Lai at MedArmor Opening
AI and Genomic Data Redefining Diagnostic Speed and Accuracy
At the heart of MedArmor’s clinical model is an innovative integration of artificial intelligence and genomic science. The clinic leverages the NextAmp Analysis System developed by NANOLAB BIOSCIENCE PTE. LTD., which incorporates the patented GenoGuard PanelChip technology. This platform enables comprehensive screening of over 56 genomic markers in a single procedure, identifying more than 100 potential hereditary conditions with a 99.4% accuracy rate.
These genomic insights are then processed through the proprietary 4DMatrix AI system, which analyzes up to 1.2 million data points per patient. This allows healthcare professionals to deliver high-precision diagnostics within under 15 minutes, far faster than the typical 72-hour diagnostic timeline.
In collaboration with the Taiwan National Health Research Institute (NHRI), MedArmor is also engaged in expanding its genomic capabilities under the “Smart Technology Integrated Community Health Care” initiative. This partnership enhances AI prediction models and extends the scope of preventative diagnostics across cardiovascular, oncological, and neurodegenerative conditions.
MedArmor Vietnam CEO Nathan (Nam) Nguyen
International Telemedicine and Gut Microbiome Screening Set as a Cross-Border Healthcare Ecosystem
Beyond genomics and AI diagnostics, MedArmor will introduce advanced gut microbiome screening in the second half of 2025. Using the high-throughput and multiplexing capabilities of the NextAmp platform, this service will offer critical insights into digestive health, immune regulation, and the gut-brain axis.
Targeting early detection and personalized treatment, MedArmor Vietnam aims to serve approximately 250,000 patients in its first year, improving early diagnosis rates by 35% and transforming how Vietnamese citizens approach long-term health management. By combining cross-border medical expertise with integrated AI analytics, MedArmor builds a future-ready medical ecosystem that can serve as a model for Southeast Asia.
